- Conditions
- Systemic Lupus Erythematosus
- Interventions
- AC0058TA, Placebo AC0058TA
- Drug
- Lead sponsor
- ACEA Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 529–552
of 562
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Epratuzumab, Placebo
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 793 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 41 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Hematopoietic stem cell transplantation
- Biological
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 15 Years to 60 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2019
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis
- Interventions
- CABA-201
- Biological
- Lead sponsor
- Cabaletta Bio
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 21
- States / cities
- Orange, California • Sacramento, California • New Haven, Connecticut + 14 more
- Conditions
- Autoimmune Diseases
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 18 Years to 115 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- estradiol, ethinyl estradiol, medroxyprogesterone, norethindrone
- Drug
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 0 Years and older · Female only
- Enrollment
- 970 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
- Conditions
- Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), Lupus Nephritis
- Interventions
- FT819, Fludarabine, Cyclophosphamide, Bendamustine
- Drug
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 12 Years to 70 Years
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2042
- U.S. locations
- 16
- States / cities
- Beverly Hills, California • Fullerton, California • Irvine, California + 13 more
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sharp's Syndrome
- Interventions
- Intravenous injection of Stromal Vascular Fraction Cells (SVF) containing ADSCs, Lipoaspiration
- Other
- Lead sponsor
- Arkansas Heart Hospital
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Curcumin supplement
- Drug
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy
- Interventions
- ADX-097
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Hollywood, Florida • Lawrenceville, Georgia • Orangeburg, South Carolina
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases, Chronic Inflammatory Syndromes, Immune Dysregulation
- Interventions
- Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN)
- Device · Drug
- Lead sponsor
- Truway Health, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Systemic Lupus Erythematosus, Physical Activity, Sleep
- Interventions
- Smartphone Application, Fitbit Activity Monitor, Coaching Sessions
- Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Systemic Lupus Erythematosus, SLE
- Interventions
- Mycophenolate Mofetil, Hydroxychloroquine or Chloroquine, Prednisone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 19
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 15 more
- Conditions
- SLE
- Interventions
- Envudeucitinib, Placebo
- Drug
- Lead sponsor
- Alumis Inc
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 48
- States / cities
- Anniston, Alabama • La Jolla, California • Los Alamitos, California + 38 more
- Conditions
- Lupus Nephritis
- Interventions
- Ianalumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 1
- States / cities
- Orchard Park, New York
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Gardasil
- Drug
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Belimumab, Rituximab, Rituximab-placebo, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • La Mesa, California • San Leandro, California + 22 more
- Conditions
- Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus
- Interventions
- DB-2304, Placebo, Prednisone
- Drug
- Lead sponsor
- DualityBio Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 6
- States / cities
- La Palma, California • Clearwater, Florida • Orlando, Florida + 3 more
- Conditions
- Refractory Lupus Nephritis, Refractory Systemic Sclerosis
- Interventions
- TAK-007, Chemotherapy Agents
- Biological · Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- TENS for vagus stimulation, TENS for sham stimulation
- Device
- Lead sponsor
- Aikaterini Thanou
- Individual
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Neonatal Lupus, Systemic Lupus Erythematosus, Sjogren's Syndrome, Congenital Heart Block
- Interventions
- No intervention; observational
- Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Mind-Body Skills Training (MBST), Supportive Counseling (SC)
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Systemic Lupus Erythematosus (Sle)
- Interventions
- Nicotinamide Riboside
- Dietary Supplement
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- High-dose immunoablative therapy
- Drug
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Philadelphia, Pennsylvania • Milwaukee, Wisconsin